CN108175763A - 一种布地奈德无菌原料及其吸入用混悬液的制备方法 - Google Patents
一种布地奈德无菌原料及其吸入用混悬液的制备方法 Download PDFInfo
- Publication number
- CN108175763A CN108175763A CN201711378009.6A CN201711378009A CN108175763A CN 108175763 A CN108175763 A CN 108175763A CN 201711378009 A CN201711378009 A CN 201711378009A CN 108175763 A CN108175763 A CN 108175763A
- Authority
- CN
- China
- Prior art keywords
- budesonide
- suspension
- preparation
- sucking
- raw material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title claims abstract description 117
- 229960004436 budesonide Drugs 0.000 title claims abstract description 117
- 239000000725 suspension Substances 0.000 title claims abstract description 80
- 239000002994 raw material Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 230000001954 sterilising effect Effects 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 35
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 238000012376 hot air sterilization Methods 0.000 claims abstract description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 21
- 238000009826 distribution Methods 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 239000003708 ampul Substances 0.000 claims description 7
- -1 polyoxyethylene Polymers 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000337 buffer salt Substances 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical group CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940068939 glyceryl monolaurate Drugs 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 claims 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 230000004888 barrier function Effects 0.000 abstract description 3
- 230000036512 infertility Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 description 28
- 238000004659 sterilization and disinfection Methods 0.000 description 23
- 239000013078 crystal Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003862 glucocorticoid Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
编号 | 原料 | 1# | 2# |
温度/℃ | / | 160 | 170 |
时间/min | / | 190 | 120 |
是否充氮 | / | 是 | 是 |
氧含量 | / | 1.3% | 2.2% |
单支组分 | 配量 |
布地奈德无菌原料 | 1.0mg |
乙二胺四乙酸二钠 | 0.2mg |
氯化钠 | 17mg |
聚山梨酯80 | 0.4mg |
无水柠檬酸 | 0.56mg |
柠檬酸钠 | 1mg |
注射用水 | 加水至2mL |
粒径d(v,0.1) | 粒径d(v,0.5) | 粒径d(v,0.9) |
0.82μm | 2.13μm | 4.14μm |
检测项目 | 实施例3 | 加速3月(40℃/75%) |
FPF[%] | 29.2 | 29.1 |
FPD[μg] | 103.3 | 104.1 |
单支组分 | 配量 |
布地奈德无菌原料 | 0.5mg |
乙二胺四乙酸二钠 | 0.2mg |
氯化钠 | 17mg |
聚山梨酯80 | 0.4mg |
无水柠檬酸 | 0.56mg |
柠檬酸钠 | 1mg |
注射用水 | 加水至2mL |
粒径d(v,0.1) | 粒径d(v,0.5) | 粒径d(v,0.9) |
0.77μm | 1.77μm | 3.80μm |
检测项目 | 0月 | 加速3月(40℃/75%) |
FPF[%] | 32.3 | 33.1 |
FPD[μg] | 52.5 | 51.9 |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711378009.6A CN108175763B (zh) | 2017-12-19 | 2017-12-19 | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711378009.6A CN108175763B (zh) | 2017-12-19 | 2017-12-19 | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108175763A true CN108175763A (zh) | 2018-06-19 |
CN108175763B CN108175763B (zh) | 2020-09-11 |
Family
ID=62546472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711378009.6A Active CN108175763B (zh) | 2017-12-19 | 2017-12-19 | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108175763B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664819A (zh) * | 2018-07-02 | 2020-01-10 | 中国药科大学 | 供吸入的齐墩果酸制剂及其制备方法与医药用途 |
CN113712942A (zh) * | 2021-04-12 | 2021-11-30 | 上海方予健康医药科技有限公司 | 一种吸入用布地奈德混悬液的制备方法 |
WO2022231532A1 (en) * | 2021-04-29 | 2022-11-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025359A1 (en) * | 1997-11-14 | 1999-05-27 | Astrazeneca Ab | New composition of matter |
WO2004060344A2 (en) * | 2002-12-19 | 2004-07-22 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
CN103565738A (zh) * | 2012-07-25 | 2014-02-12 | 天津金耀集团有限公司 | 一种快速分散的眼用水混悬液药物 |
CN104739811A (zh) * | 2015-02-27 | 2015-07-01 | 上海臣邦医药科技有限公司 | 一种糖皮质激素雾化吸入混悬液及其制备方法 |
CN107320464A (zh) * | 2017-04-28 | 2017-11-07 | 北京北朋科技有限公司 | 高ph值的布地奈德混悬液的制备方法 |
-
2017
- 2017-12-19 CN CN201711378009.6A patent/CN108175763B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025359A1 (en) * | 1997-11-14 | 1999-05-27 | Astrazeneca Ab | New composition of matter |
CN1285750A (zh) * | 1997-11-14 | 2001-02-28 | 阿斯特拉曾尼卡有限公司 | 物质的新组合物 |
WO2004060344A2 (en) * | 2002-12-19 | 2004-07-22 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
CN103565738A (zh) * | 2012-07-25 | 2014-02-12 | 天津金耀集团有限公司 | 一种快速分散的眼用水混悬液药物 |
CN104739811A (zh) * | 2015-02-27 | 2015-07-01 | 上海臣邦医药科技有限公司 | 一种糖皮质激素雾化吸入混悬液及其制备方法 |
CN107320464A (zh) * | 2017-04-28 | 2017-11-07 | 北京北朋科技有限公司 | 高ph值的布地奈德混悬液的制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664819A (zh) * | 2018-07-02 | 2020-01-10 | 中国药科大学 | 供吸入的齐墩果酸制剂及其制备方法与医药用途 |
CN113712942A (zh) * | 2021-04-12 | 2021-11-30 | 上海方予健康医药科技有限公司 | 一种吸入用布地奈德混悬液的制备方法 |
WO2022231532A1 (en) * | 2021-04-29 | 2022-11-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Also Published As
Publication number | Publication date |
---|---|
CN108175763B (zh) | 2020-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100783096B1 (ko) | 흡입운반을 위한 약제입자의 현탁물 제조방법 및 이를 이용한 무균화된 미분화 베클라메타손 디프로피오네이트 | |
CN105101955B (zh) | 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物 | |
US7541021B2 (en) | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation | |
NO346661B1 (no) | Pulverblandinger for innhalering | |
US6068832A (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
CN108175763A (zh) | 一种布地奈德无菌原料及其吸入用混悬液的制备方法 | |
Gopalan et al. | Development and evaluation of nanoemulsion and microsuspension formulations of curcuminoids for lung delivery with a novel approach to understanding the aerosol performance of nanoparticles | |
EP0927037B1 (en) | Chlorofluorocarbon-free mometasone furoate aerosol formulations | |
CN107243080B (zh) | 一种吸入式气雾剂、其原料组合物及制备方法 | |
CN107205936A (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
WO2013026269A1 (zh) | 制备用于治疗呼吸道疾病的定量喷雾吸入剂的工艺方法 | |
Morén | Dosage forms and formulations for drug administration to the respiratory tract | |
CN108175764A (zh) | 一种无水二丙酸倍氯米松无菌粉末及其吸入混悬液的制备方法 | |
CN112137957B (zh) | 一种药用吸入气雾剂及其制备方法 | |
CN106551919B (zh) | 新型吸入制剂 | |
WO2011150441A1 (en) | Medical aerosol formulation comprising ribavirin | |
Sallam | Recent Advances in the Formulation Development of Inhalational Dosage Forms | |
TR2023013885T2 (tr) | Nebuli̇zasyon yoluyla i̇nhalasyon i̇çi̇n steri̇li̇ze edi̇lmi̇ş süspansi̇yonlarin hazirlanmasi yöntemi̇ | |
WO2022231533A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
CN111939143A (zh) | 一种布地奈德溶液型气雾剂及其制备方法 | |
CN113133993A (zh) | 无菌吸入用混悬制剂及其制备方法 | |
More et al. | Formulation and Development of a “Pressurised Metered Dose Inhalation” beclomethasone 250 mcg. | |
CN115813935A (zh) | 药物组合物、气雾剂及其制备方法和气雾剂产生系统 | |
US20150290220A1 (en) | Pharmaceutical formualtions comprising a Gluococorticosteroid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Building 10, biomedical industrial park, 218 Sangtian street, Suzhou Industrial Park, Suzhou area, Suzhou pilot Free Trade Zone, 215000, Jiangsu Province Patentee after: Ruisi Pharmaceutical (Suzhou) Co.,Ltd. Address before: 215123 E143 unit, 2 floor, North Tower, A1 building, 218 Biological Park, Xing Su District, Suzhou, Jiangsu. Patentee before: YITENG PHARMACEUTICAL (SUZHOU) Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211104 Address after: 215124 No. 6, Baiyu Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee after: Suzhou sikro Pharmaceutical Co.,Ltd. Address before: 215000 building 10, biomedical industrial park, No. 218, Sangtian street, Suzhou Industrial Park, Suzhou pilot Free Trade Zone, Suzhou, Jiangsu Patentee before: Ruisi Pharmaceutical (Suzhou) Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 215021 No. 6, Baiyu Road, Suzhou Industrial Park, Jiangsu Province Patentee after: YITENG PHARMACEUTICAL (SUZHOU) Co.,Ltd. Address before: 215124 No. 6, Baiyu Road, Suzhou Industrial Park, Suzhou, Jiangsu Patentee before: Suzhou sikro Pharmaceutical Co.,Ltd. |
|
CP03 | Change of name, title or address |